GSK fights $5.2 billion IRS claim
GlaxoSmithKline (GSK), the UK-based pharmaceutical company, has received a demand for $5.2 billion in additional taxes and interest from the US Internal Revenue Service (IRS) over its transfer pricing calculations for legacy company Glaxo Wellcome from 1989 to 1996
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: